ArticleJournal of diabetes research2026
GSTP1-Mediated Inhibition of Rac1-Mineralocorticoid Receptor Signaling Underlies the Renoprotective Effect of Huangqi Tujian Decoction in Diabetic Nephropathy.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, and current therapies often fail to adequately address oxidative stress-induced podocyte injury. Huangqi Tujian Decoction (HTD), a traditional Chinese herbal formula, has shown promise in the clinical management of DN, yet its molecular mechanisms remain incompletely understood. This study aimed to elucidate the protective role of HTD and its interplay with glutathione S-transferase P1 (GSTP1) and the Rac1-mineralocorticoid receptor (MR) signaling pathway. Integrated bioinformatic analysis of human DN transcriptomes identified GSTP1 as a central hub gene. In vivo studies using db/db mice and streptozotocin-induced GSTP1-knockout models revealed that HTD significantly improved renal function; reduced albuminuria, serum creatinine, and blood urea nitrogen levels; and restored podocyte integrity markers (ZO-1 and Nephrin). HTD treatment also suppressed Rac1-MR activation and downregulated NADPH oxidase subunits, thereby alleviating oxidative stress and apoptosis. Importantly, GSTP1 deficiency completely abolished these protective effects. Coimmunoprecipitation assays demonstrated direct binding between GSTP1 and both Rac1 and MR, suggesting that GSTP1 disrupts the pathogenic Rac1-MR complex. In summary, HTD ameliorates DN by normalizing GSTP1 expression toward physiological levels, thereby disrupting the pathogenic Rac1-MR complex and attenuating oxidative damage and podocyte injury. These findings reveal a novel molecular pathway for HTD and highlight GSTP1 as a promising therapeutic target and potential biomarker for DN.
Indexed as
Identifiers
42568149What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.